Jaime Sanz, Myriam Labopin, Didier Blaise, Anna Maria Raiola, Alessandro Busca, Jan Vydra, Johanna Tischer, Patrice Chevallier, Stefania Bramanti, Renato Fanin, Gerard Socié, Edouard Forcade, Nicolaus Kröger, Yener Koc, Maija Itälä-Remes, Marco Zecca, Arnon Nagler, Eolia Brissot, Alexandros Spyridonidis, Ali Bazarbachi, Sebastian Giebel, Simona Piemontese, Mohamad Mohty, Fabio Ciceri
There is a paucity of information to guide selection of the most suitable stem cell donor in haploidentical (Haplo) hematopoietic stem cell transplantation (HSCT). For this reason, we conducted a retrospective analysis in order to evaluate the impact of Haplo family donors characteristics on HSCT outcomes in patients with acute myeloid leukemia (AML) who received graft-versus-host disease prophylaxis with post-transplant cyclophosphamide (PTCy). The primary endpoint was GvHD-free and relapse-free survival (GRFS)...
March 1, 2024: Blood Advances